1. Three-drug combination inhibits enterovirus replication in human cell and organoid cultures.
2. Protects multiple human organoids from enterovirus-mediated cell death without detectable cytotoxicity.
3. Potential application for treating enterovirus-triggered type 1 diabetes.
4. Safety profiles in humans may accelerate the pathway to clinical use against enterovirus infections.
5. Combination delays emergence of antiviral drug resistance.
6. Efficacy in human organoid models based on multitarget approach targeting different stages of the viral life cycle.
7. Pleconaril, AG7404, and mindeudesivir in the combination have completed clinical trials for other applications and have established safety profiles in humans.

Source: Cellular and Molecular Life Sciences